|
Age | 74 岁 |
|
patients with coronary heart disease | Yes
|
|
Sign the informed consent | Yes
|
|
Risk stratification for patients with low or middle risk | middle risk
|
|
Patients in one of the following condition are excluded | none
|
|
Name | QIZR |
|
gender | 女 |
|
people | 汉 |
|
Height | 156 cm |
|
weight | 63.3 kg |
|
abdomen circumference | 89 cm |
|
left ventricular ejection fraction(LVEF) | 57 |
|
stents implanted | Yes
|
|
anamnesis | hypertension
/diabetes
/arrhythmia
/heart failure
/others
|
|
Body Mass Index | 26.01 kg/m2 |
|
smoking history | No
|
|
blood cholesterol level in hospital | 3.83 mmol/l |
|
drink history | No
|
|
Bad mood performance | depression
|
|
exercise habit | No
|
|
The drug | antiplatelet drug
/others
|
|
heart rate in anaerobic domain | 98 次/分 |
|
heart rate in the peak oxygen uptake | 108 次/分 |
|
blood pressure in Anaerobic domain | 173/83 mm/Hg |
|
blood pressure in the peak oxygen uptake | 215/89 mm/Hg |
|
the oxygen uptake in the rest | 0.232 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | 0.855 ml/kg/min |
|
Peak oxygen uptake | 1.090 ml/kg/min |
|
target heart rate | 93 次/分 |
|
Treadmill load | 37 w |
|
blood pressure in the rest | 79 次/分 |
|
blood pressure in the rest | 140/84 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
heart rate in anaerobic domain | 92 次/分 |
|
heart rate in the peak oxygen uptake | 94 次/分 |
|
blood pressure in the rest | 156/76 mm/Hg |
|
blood lipid level in Peak oxygen uptake period | 188/79 mm/Hg |
|
the oxygen uptake in the rest | 0.247 ml/kg/min |
|
the oxygen uptake in anaerobic threshold | 0.629 ml/kg/min |
|
Peak oxygen uptake | 1.301 ml/kg/min |
|
target heart rate | 90 次/分 |
|
Treadmill load | 42 w |
|
heart rate in the rest | 64 次/分 |
|
blood pressure in the rest | 119/66 mm/Hg |
|
Phosphodiesterase 9A | ng/ml |
|
Inflammatory factors | ng/ml |
|
Immune-modulatory marker | ng/ml |
|
left ventricular dysfunction marker | ng/ml |
|
myeloperoxidase | ng/ml |
|
adiponectin | ng/ml |
|
extracellular-matrix remodeling markers | ng/ml |
|
Patients with follow-up of 3 months is discomfort or not | Yes
|
|
stick to exercise or not in the follow-up after 3 months | Yes
|